Education and Training
GEnder Dysphoria Treatment in Sweden
Gender dysphoria (DSM-5) or transsexualism (ICD10) is a condition in which a person's feeling of gender identity is not congruent with the physical body. The hormonal treatment includes inhibition of one's own sex hormone production followed by treatment with testosterone or estrogen levels that are normal for the opposite sex. Seen as experimental model, this is a process that provides an opportunity to study the sex hormone dependent influences that explain differences in morbidity in men and women respectively. The differences that are especially significant but not well known is 1) metabolic changes in the regulation of glucose homeostasis and lipid metabolism 2) regulation of vascular function and structural effects on the heart and arteries 3) regulation of skeletal muscle mass and fat tissue 4) morphological and functional effects on discrete areas of the brain.
Therefore, the investigators will follow these patients for a year to study how the heart, blood vessels, brain, and risk factors for cardiovascular disease affected by altered sex hormone patterns and studying what happens in the muscles and fat in both the short and long term with respect to particular gene expression and epigenetic changes and link it to metabolic changes and body composition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Genetic men treated with estrogen
- other: Genetic women treated with androgen
Eligibility
Inclusion Criteria:
- Otherwise healthy
Exclusion Criteria:
- Infectious disease
- Treatment with Warfarin or other anti coagulants.
- History of cardiovascular disease.
- Serious illness or mental disorder.
- Diabetes type 1
- Language difficulties
Ages Eligible for Study
20 Years - 40 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting